The purpose of this study is to provide patients with AMTAGVI (lifileucel) that is Out of Specification for Commercial Release.
   
In this study, AMTAGVI will be given intravenously (meaning through a needle in the vein directly into the blood).

Participation is expected to last up to 24 months.

The overall objective of our proposal is to gain a comprehensive understanding of the quality of online information about prostate cancer and to investigate the link between consumption of online information with attitudes toward PSA screening to help overcome barriers and reduce disparities in prostate cancer screening.
   
Aim 1: Evaluate the quality and readability of the online information regarding prostate cancer screening utilizing validated questionnaires and our manual and digital assessment tools.
   

Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions, such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM.
   

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD).

This is a prospective cohort study that aims to determine the genetic risk of intrahepatic cholestasis of pregnancy (ICP) and identify if there are underlying gene mutations that lead to ICP, progressive familial intrahepatic cholestasis (PFIC), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The primary objective of the study is to determine the prevalence, predictors, and obstetric outcomes of pathogenic cholestatic genetic variants among women diagnosed with ICP. 
   

This clinical trial is for men and women with newly diagnosed multiple myeloma who are not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT).
   
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
   

The purpose of this study is to test the safety of a drug called CA-4948 in combination with pembrolizumab for patients with metastatic urothelial cancer. This study tests different doses of the drug to determine the highest dose with manageable side effects in people.

The purpose of this research is to see if Neffy nasal spray works as well as injected epinephrine for treatment of serious allergic reaction known as anaphylaxis.